Kalpit Patel
Stock Analyst at B. Riley Securities
(2.01)
# 3,065
Out of 5,122 analysts
71
Total ratings
42.86%
Success rate
-6.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $78.12 | +49.77% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.80 | +273.55% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $8.08 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $70.20 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $13.83 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $8.63 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $63.60 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $17.49 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $43.62 | -3.71% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $46.29 | +62.02% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $79.67 | -5.86% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $99.92 | +10.09% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $7.62 | +57.48% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $6.80 | +105.88% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $20.72 | +78.57% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $42.83 | -43.96% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.34 | +161.19% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $7.54 | +19.36% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.15 | +94.17% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $8.02 | +398.75% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.63 | +84.05% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $31.02 | -35.53% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.16 | +621.15% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $20.74 | +73.58% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.33 | +3,762.66% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.31 | +1,274.05% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.00 | +150.00% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $11.32 | +783.39% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $26.27 | +185.50% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $78.12
Upside: +49.77%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.80
Upside: +273.55%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $8.08
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $70.20
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $13.83
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $8.63
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $63.60
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.49
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $43.62
Upside: -3.71%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $46.29
Upside: +62.02%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $79.67
Upside: -5.86%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $99.92
Upside: +10.09%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $7.62
Upside: +57.48%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $6.80
Upside: +105.88%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $20.72
Upside: +78.57%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $42.83
Upside: -43.96%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.34
Upside: +161.19%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $7.54
Upside: +19.36%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.15
Upside: +94.17%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $8.02
Upside: +398.75%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.63
Upside: +84.05%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $31.02
Upside: -35.53%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.16
Upside: +621.15%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $20.74
Upside: +73.58%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.33
Upside: +3,762.66%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.31
Upside: +1,274.05%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.00
Upside: +150.00%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $11.32
Upside: +783.39%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $26.27
Upside: +185.50%